Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I hope you are right HBD. But, after the rollercoaster ride Sareum has had I’m being cautious with any nearer term share price predictions.
Have a good evening.
Bill
Officemanager it’s just twisted and bitter people like you that don’t allow genuine people to ask questions. I feel sorry for anyone that has to tolerate your arrogance in real life. At least there are some nice people out there that have answered the questions I had.
Evening Billy - although 75p would get the m/cap back to pre-RF levels, it doesn't take into account the progress made since then i.e. completion of SAD & food effect stages without adverse effects and the intention to jump forward to P2a rather than P1b. Each of those steps should add to that notional 75p per share so maybe £1 is nearer the mark.
Hmmmmmm, just don't start with the not so subtle de-ramping, that's why you often get slapped down.
Smart yes relatively new to this company hence the question and thank you for your answers rather than biting my head off as sometimes a lot of investors on forums do. Appreciated.
I also have 75p in mind. It’s where the price was before Riverfort came along, accounting for the 50% or so dilution since then.
If you are new, then this question is fine. However one should argue why it so much in the first place. If it was not for the death spiral finance by RF, we would have never seen such a pathetically low SP value. So the answer to your question is that with RF chapter almost closed, the share is moving back to its original value which in my view is anywhere between 60p to 75p.
Because the deal with Riverfort worked out badly and had the share price in a death spiral. Additionally Riverfort stopped the flow of funds to Sareum and they were at risk of going under. That is thankfully now behind Sareum, hence the share price lifting.
If they need a raise or potential partnership (hopefully) why the hell did this shoot up so much with the recent news regarding the RF?
They might not need to fundraise as the Edison Report (see below) notes, "we expect the company is likely to seek non-dilutive funding in the form of a partnership".
https://www.edisoninvestmentresearch.com/?ACT=18&ID=33426
Correction. Should have read: Yes, that is correct. They need the funds to plan for and then execute the P2a trial and fund business operating expenses in the meantime. I’m expecting a raise in the Autumn.
Yes, that is correct. They need the funds to plan for and then execute the P1a trial and fund business operating expenses in the meantime. I’m expecting a raise in the Autumn.
Reading the half year report again, are they in effect saying they need to fundraise again post top line results of the MAD?
Lesson learnt- read the chairman’s comments ! Grossly under valued , even more than I thought and we all know ( sub results) .
Hi Basil - and just to add, recent RNS make reference to the SAD/MAD/food element of the trial and also P2a. No mention at all of P1b. Coupled with what they've told us regarding being able to reach concentrations in the blood where it could be therapeutic, we have a pretty nailed-on certainty that good news is on the horizon.
There are a lot of shares in the very sticky hands of some LTH's. I know I gave myself a self imposed limit of 100,000 shares but if price remains low I won't be able to help myself. Wife has given me green light to move to 200,000 if share price drops or doesn't breach 60p.
Roll on next week.
Elcap
For the avoidance of doubt: “we endeavour to be in a position to commence a Phase 2a study in psoriasis patients before the end of 2024.” - Sareum
Thank you . Much appreciated.
See Chairman's statement, half yearly report.
The multiple ascending dose (MAD) portion of SDC-1801 is nearing completion. Sareum aims to conclude this part of the trial by the end of Q2 2024. Subject to data review, additional funding and/or potential licencing opportunities, we endeavour to be in a position to commence a Phase 2a study in psoriasis patients before the end of 2024.
I see that some have suggested , that they may move to 2a without 1b. I've not seen anything anywhere where they have put that in writing and having listened/seen all the agm’s etc, I can’t say I’ve heard it. If anybody can just point me in the correct direction, I’d appreciate it greatly. Thank you.
Whilst it doesn't hurt to set a high sell price. It doesn't stop shorting the stock. It all depends who your broker is. This method has been debunked a few times on here. For most brokers, if they have your shares, they will loan them, it's as simple as that. Many here spend a lot of time thinking how to protect their investment. The answer is simple. If the compounds work and the company can remove the threat of raises and dillution. Investors, institutional and private will come and the market cap will rise. The aim of this game is not to own as many cheap shares you can. It is to get a good return on the shares you already own.
“ He was 110% correct. I have my ISA ones set at £6.
A broker cannot short sell something that is ‘in the system”
Perhaps it’s worth us all putting a upper limit sell price if it makes it harder for the shorters ??
Damion - I'm afraid I can't say I agree with anything in your second paragraph. But at least "...or maybe they just haven't got a clue what and are just bouncing from pillar to post" was comedy gold.
Enjoy the rest of your weekend.
Hi HBD, at the moment the bod haven't directly stated why the change of direction so just looking at possible reasons why the decision was made for a 2a and have taken your points onboard and not forgetting this is a double blinded trial and as such the Bod are also blind to full data.
It could have been a purely financial decision, maybe they feel they need to dose higher and a 2a would be more expandable/ suitable to see some efficacy, maybe they want some breathing space to see if a licence deal emerges or maybe they just haven't got a clue what and are just bouncing from pillar to post.
As always we will be the last to find out hopefully all will be revealed and news soon...
He was 110% correct. I have my ISA ones set at £6.
A broker cannot short sell something that is ‘in the system’